Septic arthritis resident survival guide

Vertigo; Resident Survival Guide
Overview
Causes
FIRE
Diagnosis
Treatment
Do's
Don'ts

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Iqra Qamar M.D.[2], Aditya Ganti M.B.B.S. [3]

Overview

Causes

FIRE

Diagnosis

Treatment

Empiric treatment should be commenced as soon as possible after culture samples have been obtained. The choice of empiric antibiotics should be determined on the basis of:^[1]^[2]^[3] Gram stain results of synovial fluid analysis Local prevalence of organisms and resistance patterns Predisposing factors including intravenous drug use, hospitalization, or colonization of infectious pathogens, and risk for methicillin-resistant Staphylococcus aureus (MRSA) If the patient fails to respond to initial treatment, consider:^[1] Misidentification of causative pathogen Infection with atypical pathogen Concurrent osteomyelitis Occult nidus of infection Intra-articular antibiotics are not useful as it may increase infection rate and also causes chemical synovitis and cartilage toxicity.^[4] Methicillin-resistant Staphylococcus aureus (MRSA) Patient at high risk of methicillin-resistant Staphylococcus aureus (MRSA) include:^[5]^[6] Known MRSA colonization or infection Recent hospitalization Nursing-home resident Presence of leg ulcers Indwelling catheters

Antimicrobial Regimen – Empiric Therapy:

Newborn (< 1 week)	Newborn (1–4 weeks)	Infants (1–3 months)	Children (3 months–14 years)	Adults
High Risk for MRSA Preferred Regimen Vancomycin 18 mg/kg/day IV q12h AND Cefotaxime 50 mg/kg IV q12h Low Risk for MRSA Cefotaxime 50 mg/kg IV q12h AND Nafcillin 25 mg/kg IV q8h or Oxacillin 25 mg/kg IV q8h	High Risk for MRSA Preferred Regimen Vancomycin 22 mg/kg/day IV q12h AND Cefotaxime 50 mg/kg IV q8h Alternative Regimen Clindamycin 5 mg/kg IV q8h Low Risk for MRSA Preferred Regimen Cefotaxime 50 mg/kg IV q8h AND Nafcillin 37 mg/kg IV q6h OR Oxacillin 37 mg/kg IV q6h Alternative Regimen Clindamycin 5 mg/kg IV q6h	High Risk for MRSA Preferred Regimen Vancomycin 40 mg/kg/day IV q6–8h AND Cefotaxime 50 mg/kg IV q8h Low Risk for MRSA Preferred Regimen Cefotaxime 50 mg/kg IV q8h AND Nafcillin 37 mg/kg IV q6h OR Oxacillin 37 mg/kg IV q6h Alternative Regimen Clindamycin 7.5 mg/kg IV q6h	Preferred Regimen Vancomycin 40 mg/kg/day IV q6–8h AND Cefotaxime 50 mg/kg IV q8h	Monoarticular At risk for sexually-transmitted disease Preferred Regimen Ceftriaxone 1 g IV q24h OR Cefotaxime 1 g IV q8h OR Ceftizoxime 1 g IV q8h Alternative Regimen Vancomycin 1 g IV q12h Not at risk for sexually-transmitted disease Preferred Regimen Vancomycin 1 g IV q12h AND Ceftriaxone 1 g IV q24h OR Cefotaxime 1 g IV q8h OR Ceftizoxime 1 g IV q8h Alternative Regimen Vancomycin 1 g IV q12h AND Ciprofloxacin 400 mg IV q12h OR Levofloxacin 750 mg IV q 24 h Polyarticular Preferred Regimen Ceftriaxone 1 g IV q24h

Antimicrobial Regimen – Synovial Fluid Gram Stain-Based Therapy:

Gram stain result	First choice antibiotic	Second choice antibiotic
Negative Gram stain	Vancomycin 15–20 mg/kg q8–12h and Ceftazidime 2 g IV q8h or Cefepime 2 g IV q8–12h	Daptomycin 6-8 mg/kg IV q24h or Linezolid 600 mg IV/PO q12h and Piperacillin-Tazobactam 4.5 g IV q6h or Aztreonam 2 g IV q8h or Imipenem 500 mg IV q6h or Meropenem 1 g IV q8h or Doripenem 500 mg IV q8h or Carbapenems
Gram-positive cocci	Vancomycin 15–20 mg/kg q8–12h	Daptomycin 6-8 mg/kg IV q24h or Linezolid 600 mg IV/PO q12h
Gram-negative cocci	Ceftriaxone 1 g IV q24h or Cefotaxime 1 g IV q8h
Gram-negative bacilli	Ceftazidime 2 g IV q8h or Cefepime 2 g IV q8–12h or Piperacillin-Tazobactam 4.5 g IV q6h	Aztreonam 2 g IV q8h or Imipenem 500 mg IV q6h or Meropenem 1 g IV q8h or Doripenem 500 mg IV q8h or

Antimicrobial Regimen – Pathogen Based Therapy:

Microorgnaism		First choice antibiotic	Second choice antibiotic
Staphylococcus aureus	Methicillin-sensitive	Nafcillin 2 g IV QID or Clindamycin 900 mg IV TID	Cefazolin 0.25–1 g IV/IM q6–8h, Vancomycin 500 mg IV q6h or 1 g IV q12h
Staphylococcus aureus	Methicillin-resistant	Vancomycin 15–20 mg/kg IV q8–12h in adults or 15 mg/kg IV q6h in children or Linezolid 600 mg PO/IV q12h in adults or 10 mg/kg PO/IV q8h in children	Sulfamethoxazole-trimethoprim 3.5–4.0 mg/kg PO/IV q8–12h in adults or Minocycline ± rifampin
Coagulase-negative Staphylococcus spp	Methicillin-sensitive	Nafcillin 2 g IV QID or Clindamycin 900 mg IV/IM TID	Cefazolin 0.25–1 g IV/IM q6–8h vancomycin 500 mg IV q6h or 1 g IV BD
Coagulase-negative Staphylococcus spp	Methicillin-resistant	Vancomycin 1 g BD or Linezolid 600 mg BD	Sulfamethoxazole-trimethoprim or Minocycline ± rifampin or Clindamycin
Group A streptococcus, Strep. pyogenes		Penicillin G 2 million IV/IM every 4 h or Ampicillin 2 g IV QID	Clindamycin 600–1200 mg/day IV/IM q6–12h Cefazolin 0.25–1 g IV/IM q6–8h
Group B streptococcus, Strep. agalactiae		Penicillin G 2 million IV/IM every 4 h or Ampicillin 2 g IV every 6 h	Clindamycin 600–1200 mg/day IV/IM q6–12h Cefazolin 0.25–1 g IV/IM q6–8h
Enterococcus spp.		Ampicillin 2 g IV QID or Vancomycin 1 g IV BD	Ampicillin-sulbactam 3 g IV QID Linezolid 600 mg PO/IV BD
Escherichia coli		Ampicillin-sulbactam 3 g IV QID	Cefazolin 0.25–1 g IV/IM q6–8h, levofloxacin 500–750 mg IV/PO OD Gentamicin 3–5 mg/kg/day IV q6–8h Sulfamethoxazole-trimethoprim 8–10 mg/kg/day IV/PO q6–12h
Proteus mirabilis		Ampicillin 2 g IV QID or Levofloxacin 500 mg IV/PO OD	Cefazolin 0.25–1 g IV/IM q6–8h Sulfamethoxazole-trimethoprim 8–10 mg/kg/day IV/PO q6–12h Gentamicin 3–5 mg/kg/day IV q6–8h
Proteus vulgaris, Proteus rettgeri, Morganella morganii		Cefotaxime 2 g IV QID Imipenem 500 mg IV QID, or Levofloxacin 500 mg IV/PO OD	Gentamicin 3–5 mg/kg/day IV q6–8h, or Ticarcillin-clavulanate 3.1 g IV q4–6h
Serratia marcescens		Cefotaxime 2 g IV QID	Levofloxacin 500 mg IV/PO OD Gentamicin 3–5 mg/kg/day IV q6–8h Imipenem 500 mg IV QID
Pseudomonas aeruginosa		Cefepime 2 gm IV BD or Piperacillin 3 gm IV QID or Imipenem 500 IV QID	Ticarcillin-clavulanate 3.1 g IV q4–6h Tobramycin 3-5 mg/kg/day IV q6–8h Amikacin 15 mg/kg/day IV/IM q8–12h Ciprofloxacin 400 mg IV q8–12h
Neisseria gonorrhea		Ceftriaxone 2 g IV OD or Cefotaxime 1 g TID	Levofloxacin 500 mg IV/PO OD Ampicillin 2 g IV QID
Bacteroides fragilis group		Clindamycin 900 mg IV/IM TID or Metronidazole 500 mg TID	Ampicillin-sulbactam 3 g IV QID or Ticarcillin-clavulanic acid 3.1 g IV QID
Brucella melitensis		Doxycycline 100 mg PO BD and Streptomycin 15 mg/kg IM QID or Rifampin 600–900 mg QID	Doxycycline 100 mg PO BD and Gentamicin 5 mg/kg IV QID
Haemophilus influenzae		Amoxicillin-Clavulanate 875/125 mg PO BD or Cefprozil 500 mg PO BD or Cefuroxime 500 mg PO BD or Cefdinir 600 mg PO OD	Levofloxacin 750 mg IV/PO OD or Moxifloxacin 400 mg IV/PO OD or Clarithromycin 500 mg PO BD
Morganella morganii		Cefotaxime 2 g IV QID or Imipenem 500 mg IV QID or Levofloxacin 500 mg IV/PO OD	Gentamicin 3–5 mg/kg/day IV q6–8h or Ticarcillin-Clavulanate 3.1 g IV q4–6h
Tropheryma whipplei		Penicillin G 2 million units IV q4h for 2 weeks and Streptomycin 1 g IM/IV OD for 2 weeks, then TMP-SMX 160mg/800mg PO OD for 1 year	Ceftriaxone 2 g IV OD, then TMP-SMX 160mg/800mg PO OD for 1 year
Borrelia burgdorferi		Amoxicillin 500 mg TID for 28 days or Doxycycline 100 mg BD for 28 days or Cefuroxime 500 mg BD for 28 days	Azithromycin 500 mg PO OD for 7–10 days or Clarithromycin 500 mg PO BD for 14–21 days or Erythromycin 500 mg PO QID for 14–21 days

Duration of Antimicrobial Therapy:

Do's

Don'ts

References

↑ ^1.0 ^1.1 Shirtliff ME, Mader JT (2002) Acute septic arthritis. Clin Microbiol Rev 15 (4):527-44. PMID: 12364368
↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
↑ Mathews, Catherine J.; Weston, Vivienne C.; Jones, Adrian; Field, Max; Coakley, Gerald (2010-03-06). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–855. doi:10.1016/S0140-6736(09)61595-6. ISSN 1474-547X. PMID 20206778.
↑ Stutz G, Kuster MS, Kleinstück F, Gächter A (2000) Arthroscopic management of septic arthritis: stages of infection and results. Knee Surg Sports Traumatol Arthrosc 8 (5):270-4. DOI:10.1007/s001670000129 PMID: 11061294
↑ Liu, Catherine; Bayer, Arnold; Cosgrove, Sara E.; Daum, Robert S.; Fridkin, Scott K.; Gorwitz, Rachel J.; Kaplan, Sheldon L.; Karchmer, Adolf W.; Levine, Donald P.; Murray, Barbara E.; J Rybak, Michael; Talan, David A.; Chambers, Henry F.; Infectious Diseases Society of America (2011-02-01). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (3): –18-55. doi:10.1093/cid/ciq146. ISSN 1537-6591. PMID 21208910.
↑ Sharff KA, Richards EP, Townes JM (2013) Clinical management of septic arthritis. Curr Rheumatol Rep 15 (6):332. DOI:10.1007/s11926-013-0332-4 PMID: 23591823

[pmid12364368-1] 1.0 ^1.1 Shirtliff ME, Mader JT (2002) Acute septic arthritis. Clin Microbiol Rev 15 (4):527-44. PMID: 12364368

[2] Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.

[3] Mathews, Catherine J.; Weston, Vivienne C.; Jones, Adrian; Field, Max; Coakley, Gerald (2010-03-06). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–855. doi:10.1016/S0140-6736(09)61595-6. ISSN 1474-547X. PMID 20206778.

[pmid11061294-4] Stutz G, Kuster MS, Kleinstück F, Gächter A (2000) Arthroscopic management of septic arthritis: stages of infection and results. Knee Surg Sports Traumatol Arthrosc 8 (5):270-4. DOI:10.1007/s001670000129 PMID: 11061294

[5] Liu, Catherine; Bayer, Arnold; Cosgrove, Sara E.; Daum, Robert S.; Fridkin, Scott K.; Gorwitz, Rachel J.; Kaplan, Sheldon L.; Karchmer, Adolf W.; Levine, Donald P.; Murray, Barbara E.; J Rybak, Michael; Talan, David A.; Chambers, Henry F.; Infectious Diseases Society of America (2011-02-01). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 52 (3): –18-55. doi:10.1093/cid/ciq146. ISSN 1537-6591. PMID 21208910.

[pmid23591823-6] Sharff KA, Richards EP, Townes JM (2013) Clinical management of septic arthritis. Curr Rheumatol Rep 15 (6):332. DOI:10.1007/s11926-013-0332-4 PMID: 23591823

[1]

[2]

[3]

[4]

[5]

[6]

Septic arthritis resident survival guide

Overview

Causes

FIRE

Diagnosis

Treatment

Methicillin-resistant Staphylococcus aureus (MRSA)

Antimicrobial Regimen – Empiric Therapy:

Antimicrobial Regimen – Synovial Fluid Gram Stain-Based Therapy:

Antimicrobial Regimen – Pathogen Based Therapy:

Duration of Antimicrobial Therapy:

Do's

Don'ts

References

Navigation menu